GHK-Cu Capsule
Product Overview
GHK-Cu is a naturally occurring copper peptide found in the body that may play a role in tissue repair and cell signaling. It has mainly been studied for its ability to support collagen production, calm inflammation, and support skin and tissue repair.[1,2]
Most human research on GHK-Cu comes from topical use (applied to the skin), not oral use. Research on GHK-Cu is still mostly limited to animal and laboratory studies, and how well the body absorbs GHK-Cu when taken by mouth is not yet well understood. GHK-Cu is not approved by the U.S. Food and Drug Administration for any use.
Use should be guided by a licensed healthcare provider with consideration of the available evidence.
The information below reflects a commonly used dosing approach for this product. It is provided for general information only and is not a dosing recommendation. A prescribing provider may select a different amount, frequency, or duration based on the patient’s treatment goals, response, tolerability, medical history, concomitant therapies, and other patient-specific factors.
Take 1 capsule by mouth once daily.
Your prescribed amount, strength, frequency, or duration may differ from the common dosing information shown above. Use this medication only as directed on your prescription label, and do not change how you use it unless instructed by your prescribing provider. Contact your provider or pharmacist if you have questions about your individualized directions.
GHK-Cu exerts its effects through multiple biologic pathways involved in tissue repair and cellular regulation.[1,2]
Proposed mechanisms include:[1,2]
Collagen synthesis and extracellular matrix remodeling: GHK-Cu has been shown to stimulate production of collagen, elastin, and glycosaminoglycans, contributing to structural integrity of tissues.
Modulation of gene expression: Bioinformatic analyses suggest that GHK-Cu influences the expression of genes involved in tissue repair, inflammation, and antioxidant defense.
Anti-inflammatory activity: GHK-Cu has demonstrated the ability to modulate inflammatory cytokines and reduce oxidative stress in experimental models.
Angiogenesis and tissue regeneration: The peptide has been associated with enhanced vascularization and improved wound healing responses.
These mechanisms have been primarily characterized in laboratory and dermatologic studies. The clinical implications of oral administration have not been established in human trials.
Due to limited human data, GHK-Cu capsules should be used with caution.
- Limited clinical data are available for oral use
- Use caution in patients with Wilson disease, impaired bile excretion, or with additional copper-containing supplements.[3]
- Avoid use in patients with active malignancy due to potential effects on cellular growth and remodeling
- Long-term safety data are not available
Therapy should be individualized and supervised by a qualified healthcare provider.
Formal drug interaction studies have not been conducted.
Given its copper content and proposed effects on inflammatory signaling, theoretical interactions may occur with:
- Agents affecting copper metabolism[3]
- Therapies influencing wound healing or inflammatory pathways
- Antioxidant or anti-inflammatory medications
Patients should disclose all medications and supplements prior to initiation.
Human adverse effect data for oral GHK-Cu are not available. Based on available data and mechanism of action, potential side effects may include:
- Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal discomfort
- Excess copper exposure: possible liver injury; severe toxicity may also affect the kidneys and blood cells
Further clinical evaluation is needed to establish a comprehensive safety profile.
Any suspected side effects, medication errors, and concerns about this medication, such as the wrong strength, possible contamination, or problems with labeling or packaging, should be reported to the prescribing healthcare provider, Empower Pharmacy, and the FDA through MedWatch. For this compounded medication, reports should also be submitted to the appropriate state regulatory authority where the product was compounded and the state where it was shipped, if different.
GHK-Cu has not been adequately studied in pregnant or breastfeeding individuals.
Due to limited safety data and its effects on cellular signaling and tissue remodeling, use during pregnancy and breastfeeding is contraindicated.
Proper storage of GHK-Cu capsules is important to maintain stability and consistency.
- Storage: Room temperature (68-77°F (20-25°C))
Do not use beyond the beyond-use date provided by Empower.
Disclaimer
Compounded products are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. Compounded products from our 503A facility are available only through a valid patient-specific prescription from a licensed prescriber and are prepared by a licensed pharmacy; shipping and state restrictions may apply. Compounded drug products from our 503B facility are only available for order by licensed healthcare providers and pharmacies. This document is for educational and informational use by healthcare professionals. It is not medical, legal, or regulatory advice, and it is not a promotion of any product. Except for products identified as currently available, it is not a statement of product availability.
Regulatory status
HHS’s interim policy is an expression of enforcement intent under stated conditions; it does not approve any product, change the requirements of the FD&C Act, or place any substance on the 503A Bulks List, which requires FDA rulemaking. PCAC recommendations are advisory. No dose of this product has been established as safe or effective in humans. State boards of pharmacy and medicine independently regulate compounding and prescribing. Regulatory status can change; confirm current status with FDA, HHS, and applicable state authorities before relying on this summary.
Reporting
Healthcare professionals and patients are encouraged to report suspected adverse events and product quality concerns to FDA MedWatch (fda.gov/medwatch; 1-800-FDA-1088).
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108
- Food and Drug Administration. Copper (cupric chloride) [package insert]. DailyMed. Updated May 18, 2026. Accessed November 2, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc
What Is the HHS Peptide Enforcement Discretion Policy?
HHS’s peptide enforcement discretion policy is a statement that it does not intend to take enforcement action against certain peptide compounding when specific conditions are met. It is a draft interim policy that is not binding on HHS or the public, and it does not change Section 503A. The policy stays in place while FDA builds the 503A bulk drug substances list through rulemaking. It applies to state-licensed pharmacies, Federal facilities, and licensed physicians. A “licensed physician” here means one who compounds, not prescribers in general.
For prescribers, this changes the federal enforcement picture for the pharmacies you can work with, but it does not impact any state-specific laws or regulations that may exist in your state.
Which Peptides Does the Policy Cover?
Six: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Each is limited to the specific form and routes listed. A peptide not on the list, or in a different form or route, is outside the policy.
Source: Appendix B of the HHS policy. Appendix B defines each peptide by exact sequence and formula. For instance, it describes TB-500 as a fragment of its parent protein, thymosin beta-4. The full text is in the Federal Register notice.
Do Prescribers Need a Patient-Specific Prescription?
Yes. The policy names section 503A’s patient-specific prescription requirement as one of its conditions The clinical decision for each patient is still yours. Consider documenting:
- Your clinical rationale for each individual patient
- Patient consent, including that the product is compounded and not FDA-approved
- The specific peptide, form, and route, checked against Appendix B
Is a Compounded Peptide FDA-Approved?
No. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed. None of these six peptides is an FDA-approved drug.
HHS states that its policy is meant to expand patient access while FDA reviews these substances. Enforcement discretion describes how HHS intends to use its enforcement resources. It is not an approval of any peptide or compounded product.
Where did the active ingredient come from?
An FDA-registered original manufacturer, with a Certificate of Analysis reviewed for each lot.
Can I see testing, not just a purity number?
Each batch is released with a Certificate of Conformance. Prescribers can request it.
What is a COC, and what is a COA?
A Certificate of Conformance (COC) is Empower’s batch-release document for a finished peptide; prescribers can request it. A Certificate of Analysis (COA) comes from the active ingredient manufacturer for each lot and, as reported, must show the manufacturer’s location under the HHS policy. Confirm details in the policy text.
503A vs 503B
- 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
- 503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.
Frequently asked questions
Our team of experts has the answers you're looking for.
A clinical pharmacist cannot recommend a specific doctor. Because we are licensed in all 50 states*, we can accept prescriptions from many licensed prescribers if the prescription is written within their scope of practice and with a valid patient-practitioner relationship.
*Licensing is subject to change.
Each injectable IV product will have the osmolarity listed on the label located on the vial.

Given the vastness and uniqueness of individualized compounded formulations, it is impossible to list every potential compound we offer. To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (877) 562-8577.
We source all our medications and active pharmaceutical ingredients from FDA-registered suppliers and manufacturers.

Wolverine Stack
Glow Stack
Klow Stack
BPC-157 Acetate Injection
TB-500 Acetate Injection
KPV Acetate Capsule
MOTS-c Acetate Injection
GHK-Cu Facial Serum
GHK-Cu Scalp Solution
Glutathione Injection
Sermorelin Acetate Injection
NAD+ Injection (Aqueous)